No Data
Frontage Holdings Appoints Co-CEOs
FRONTAGE (01521.HK): Wentao Zhang and Zhongping Lin have been promoted to co-CEOs.
Gelonghui, January 6th | FRONTAGE (01521.HK) announced that Dr. Abdul Mutlib has decided to step down from his current position as the company's CEO effective January 6, 2025, to facilitate the company's leadership succession plan. As of January 6, 2025, Dr. Wentao Zhang, the Chief Strategy Officer of the company's wholly-owned subsidiary Frontage Laboratories, Inc. ('Frontage Labs'), and
Express News | Frontage Holdings - Wentao Zhang and Zhongping Lin Promoted to Co-Ceos
Express News | Frontage Holdings - Abdul Mutlib to Step Aside From His Current Role as CEO
FRONTAGE (01521.HK) was increased shareholding by Hongkong Tigermed Co., Limited by 1.064 million shares.
On January 3, Glory Holdings reported that according to the latest equity disclosure data from the Stock Exchange, on December 31, 2024, FRONTAGE (01521.HK) was increased by Hongkong Tigermed Co., Limited in the market, acquiring 1.064 million shares at an average price of HKD 1.773 per share, involving approximately HKD 1.1865 million. After the shareholding increase, the latest number of shares held by Hongkong Tigermed Co., Limited is 1,079,664,090 shares, with the shareholding ratio rising from 52.98% to 53.04%.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Despite Hitting HK$1.67, Frontage Holdings Insiders Still Sold Too Soon
